Some studies have shown that cystatin C is not trustworthy for GFR marker in ovarian cancer because of its nature as a cysteine protease inhibitor34, and the concentration variations in serum cystatin C might underestimate eGFR in esophageal cancer35. This evidence concerns the gene CTSB and ovarian carcinoma.